Replies to post #323789 on Anavex Life Sciences Corp (AVXL)

[vg_future]

Thanks for the post raja48185. This shows lot of things about the whole SAVA stuff
- how analysts pumped it
- how SAVA re-worked the data after initial failure announcement (like Biogen)
- how SAVA is desperate to sell itself to someone else

I wish Anavex gets its real recognition soon and not get caught in the SAVA and Annovis non-sense/noise/manipulation.

-vg_future

[Investor2014]

This is the kind of critique that when printed about the AD stocks I am not invested in is absolutely spot on, but makes me really upset and frustrated if about $AVXL. Then clearly the nefarious work of the cabal.

Well anyway that was great post about Cassava and so right not least because now all the silly $SAVA investors will see the error of their ways and come to $AVXL with the smouldering remains of their hard earned savings,

[georgejjl]

raja, I am just asking.

Has anyone anyone found these same quotes that you quoted anywhere on the internet?

I am just looking for back up evidence.

GOD bless,

[tredenwater2]

Lon Schneider, a physician and Alzheimer’s expert at the Keck School of Medicine of the University of Southern California, described Cassava’s study results as “uninterpretable.”

Thats interesting news Raja. Ironically in all of Anavex’s data releases, the only “uninterpretable” data for us has come from those on this board….oh and AF.

:)

[frrol]

The Cassava results are promising, as was our small open label phase 2a. There's a big limit on its reliability, however. It's not 'proof'. They'll have to confirm it in a large, controlled trial. As we're doing. That's biotech. We're not in the magic bean business.

We're farther along, with supportive controlled trial data, and an arguably broader MOA. Capital markets adjust, and that will serve us relatively well. Our market cap gap has narrowed.

Folks can relax. No one is trying to steal your shares or hurt your stock speculating.

[Bourbon_on_my_cornflakes]

Raja sees clearly: Cassava’s study results as “uninterpretable.” Asked by STAT to examine the simufilam data, Alzheimer’ scientists not involved in Cassava’s study said the cognitive benefit claim was exaggerated and not supported by the design of the clinical trial.

Spot on. I've noticed all along that the big thing about SAVA is they designed their own diagnostic instead of using standard tests
.
Imagine if you will a football game where instead of touchdowns and field goals as determining the score, you instead said that what matters is "first down yardage".

Now those who know the game know that "first down yardage" may be an indicator of success in some circumstances, as big first down yardage opens up second down as an opportunity to try a wider, risker group of plays, and you still have 3rd down to get another first down.

But, this could also be gamed. You could design a team with a big running back and offensive line by sacrificing picks for receivers and QB. You would get big first down yardage but ultimately not score as the defense would start only playing the run.

OR, more likely in Sava's case, you could change the rules of football to denote winning as first down yardage if that is all your team is good for.

And note that SAVA's good lawyers are very careful to have mgt say the team is good at first down yardage, which they "believe" correlates with scoring, but they do not say they are scoring.

Until SAVA shows they can score with the standard tests, they deserve scepticism.

[PeterKarol]

We have to ask ourself a question. Is all about simufilam or about defense of Aduhelm? I have no subscription and don’t intend to spent the money. What I gather from the language used this is mostly ad hominem like “undergrad”. From the top data you can’t tell that. Are they in possession of individual patient data? because only then you can say those things. The individual patients data went through statistical grinder and is like a sausage. You don’t see the separate ingredients.
On the other hand, the reputation of the CEO does not engender confidence.
Simufilam is indeed a serious contender to Aduhelm and people like AF need to put food on the on the table. P just saying

[Bourbon_on_my_cornflakes]

Best of Prof. Rob Howard:

"The FDA’s assertion that there is a meaningful association between reducing amyloid and subsequent cognitive and functional decline in the anti-amyloid trials in AD just isn’t true. You can see why they and the companies would want to establish this narrative, but it is false"

"We all expect to make changes to our papers as part of the peer review process. I presume that Biogen wouldn’t make the changes that reviewers and the editor told them were needed for acceptance for publication. Once again, Biogen actively avoid conventional scientific scrutiny."